Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Caffeine pterostilbene co-crystal is a relatively new compound combining caffeine—a well-known stimulant—and pterostilbene, a polyphenol structurally related to resveratrol. While both components have individually been studied for potential metabolic effects, the co-crystal form is primarily investigated for improved bioavailability and tolerability rather than direct metabolic syndrome treatment effects.

Scientific evidence for the use of caffeine pterostilbene to support or treat metabolic syndrome is limited but emerging. Some preclinical studies and small human trials suggest that pterostilbene can positively influence glucose metabolism, lipid profiles, and oxidative stress, all relevant to metabolic syndrome. Caffeine, separately, has been linked to increased energy expenditure and improved insulin sensitivity in some studies. However, the literature on the specific co-crystal is sparse, with only a few clinical trials (e.g., Udani et al., 2013) indicating improved pharmacokinetics and safety compared to caffeine alone, but not directly addressing metabolic syndrome endpoints.

In summary, while there is a scientific rationale based on the actions of the individual components, and some early studies with the co-crystal, robust clinical evidence for using caffeine pterostilbene specifically for metabolic syndrome is lacking. More high-quality, direct research is needed before firm recommendations can be made.

More about Caffeine pterostilbene
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Caffeine pterostilbene

Products containing Caffeine pterostilbene